| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 159,933 | 166,496 | 139,292 | 139,494 |
| Cost of sales | 27,991 | 23,002 | 28,662 | 21,021 |
| Research and development | 216,212 | 164,736 | 165,772 | 170,109 |
| Selling, general and administrative | 86,620 | 86,646 | 87,797 | 80,351 |
| Total operating expenses | 330,823 | 274,384 | 282,231 | 271,481 |
| Loss from operations | -170,890 | -107,888 | -142,939 | -131,987 |
| Interest income | 5,863 | 5,794 | 6,831 | 10,731 |
| Change in fair value of equity investments | 678 | -9 | -157 | 678 |
| Non-cash interest expense on liabilities for sales of future royalties | 14,148 | 14,041 | 14,342 | 15,712 |
| Other (expense) income | -1,043 | 2,140 | 837 | 3,077 |
| Loss before income taxes | -179,540 | -114,004 | -149,770 | -133,213 |
| Provision for income taxes | 873 | 947 | 1,310 | 303 |
| Net loss | -180,413 | -114,951 | -151,080 | -133,516 |
| Earnings per share, basic, total | -1.81 | -1.17 | -1.57 | -1.4 |
| Earnings per share, diluted, total | -1.81 | -1.17 | -1.57 | -1.4 |
| Weighted average number of shares outstanding, basic, total | 99,771,297 | 98,460,445 | 96,288,650 | 95,493,996 |
| Weighted average number of shares outstanding, diluted, total | 99,771,297 | 98,460,445 | 96,288,650 | 95,493,996 |
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)